Vitura HealthASX:VIT PB Ratio is 0.39 as of Jul. 06, 2026, which is 74% below its 10-year median of 1.48. The stock has 8 warning signs investors should review. Among 921 Drug Manufacturers companies, Vitura Health ranks better than 94.46% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-06), Vitura Health's share price is A$0.027. Vitura Health's Book Value per Share for the quarter that ended in Dec. 2025 was A$0.07. Hence, Vitura Health's PB Ratio of today is 0.39.
The historical rank and industry rank for Vitura Health's PB Ratio or its related term are showing as below:
ASX:VIT'
s PB Ratio Range Over the Past 10 Years
Min: 0.3 Med: 1.48 Max: 19.04
Current: 0.39
During the past 7 years, Vitura Health's highest PB Ratio was 19.04. The lowest was 0.30. And the median was 1.48.
ASX:VIT's PB Ratio is ranked better than 94.46% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.93
vs ASX:VIT: 0.39
During the past 3 years, the average Book Value Per Share Growth Rate was 15.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -4.70% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Vitura Health was 15.80% per year. The lowest was -24.70% per year. And the median was -8.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Vitura Health PB Ratio Related Terms
Vitura Health PB Ratio Historical Data
* Premium members only.
The historical data trend for Vitura Health's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vitura Health's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitura Health PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vitura Health's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vitura Health's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Vitura Health's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vitura Health (ASX:VIT) has a PB Ratio of 0.39 as of Jul. 06, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vitura Health and its competitors. This is 74% below median its historical median of 1.48. Over the past decade, Vitura Health's PB Ratio has ranged from 0.30 to 19.04. According to the industry distribution chart, Vitura Health ranks #51 out of 921 companies in the Drug Manufacturers industry, placing it in the top 5.5%.
Is Vitura Health's PB Ratio too high?
Vitura Health's current PB Ratio of 0.39 is 74% below median its 10-year median of 1.48. Over the past 10 years, this metric has ranged from a low of 0.30 to a high of 19.04. The Drug Manufacturers industry median PB Ratio is 1.93. Vitura Health's value of 0.39 is 79.8% below this industry median. Based on the distribution chart, Vitura Health ranks #51 out of 921 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Vitura Health's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vitura Health ranks #51 out of 921 companies for PB Ratio. This places Vitura Health in the top 6% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.93. Vitura Health's value of 0.39 is 79.8% below this benchmark. Historically, Vitura Health's own PB Ratio has ranged from 0.30 to 19.04 over the past decade. While the company's 10-year median is 1.48 vs. the industry median of 1.93, Vitura Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.93, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitura Health's current PB Ratio of 0.39 is 79.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vitura Health and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitura Health's current PB Ratio is 0.39, which is 74% below median its own 10-year median of 1.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitura Health stock overvalued right now?
Based on GuruFocus' analysis, Vitura Health (ASX:VIT) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.10, compared to a current price of A$0.03 — trading 73% below its estimated fair value. The current PB Ratio is 0.39, which is 74% below median its 10-year median of 1.48 and 79.8% below the Drug Manufacturers industry median of 1.93. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vitura Health (ASX:VIT), the current PB Ratio is 0.39 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitura Health Ltd is focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the ecosystem between patients, prescribers, pharmacists, and suppliers. The company has two business segments namely, Sales and distribution (involving the sale and distribution of medical products including medicinal cannabis, psychedelic drugs, and smoking cessation products) and Clinics and services (involving the operation of medicinal cannabis clinics and the provision of related services). The company generates the majority of its revenue from the Sales and distribution segment. Geographically the company generates the majority of its revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VIT has been successfully added to your 